Prospect News: News for Sorrento Therapeutics, Inc.

E-mail us: service@prospectnews.com Or call: 212 374 2800

Bank Loans - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products

Price: $0.00

Account balance: $0.00

Add to balance / Manage account

User: lxbfYeaa

Log out

Prospect News home > Main news index > All issuers starting with S > Issuers starting with S, DD only > All stories on Sorrento Therapeutics, Inc. > Stories on Sorrento Therapeutics, Inc., DD only

Search again

Enter part or all of the issuer name:

Market:

All markets No structured products Bank loans Canadian bonds CLOs Convertibles Distressed debt Emerging markets High yield Investment grade Liability management Municipals PIPEs Preferreds Private placements All leveraged markets Structured products

Market: BK = Bank loans, CV = Convertibles, DD = Distressed Debt, EM = Emerging Markets, HY = High Yield, IG = Investment Grade, LM = Liability Management, MU = Municipals, PP = PIPEs, PF = Preferreds, PV = Private Placements, SP = Structured Products
Recent items, highlighted in orange, are $4.00 each. All others are $1.00 each. Headlines in gray are not currently covered by your subscription.

Sorrento Therapeutics, Inc.

4/11/2024	DD	Sorrento Therapeutics’ plan of liquidation effective as of April 10
3/12/2024	DD	Sorrento Therapeutics gets final approval of $5 million DIP facility
3/12/2024	DD	Sorrento Therapeutics’ case to stay open in Texas, court rules
3/4/2024	DD	Sorrento Therapeutics gets interim access to $5 million DIP facility
3/4/2024	DD	Sorrento Therapeutics, Scilex reach settlement with Virpax
3/1/2024	DD	Sorrento Therapeutics reports $5.07 million net loss for January
2/23/2024	DD	Sorrento Therapeutics’ DIP motion draws U.S. trustee objection
2/20/2024	DD	Sorrento Therapeutics eyes $5 million DIP facility with BioVintage
2/20/2024	DD	Sorrento Therapeutics’ case should be moved or dismissed, trustee says
2/6/2024	DD	Sorrento Therapeutics gets sixth extension of exclusive plan periods
1/9/2024	DD	Sorrento Therapeutics seeks sixth extension of exclusive plan periods
12/19/2023	DD	Sorrento Therapeutics gets fifth extension of exclusive plan periods
12/1/2023	DD	Sorrento Therapeutics receives confirmation of plan of liquidation
11/27/2023	DD	Sorrento Therapeutics seeks fifth extension of exclusive plan periods
11/17/2023	DD	Sorrento Therapeutics plan hearing moved, voting results given
11/16/2023	DD	Sorrento Therapeutics reports $100.7 million net profit for September
11/13/2023	DD	Sorrento Therapeutics’ plan draws objection from equity committee
11/3/2023	DD	Sorrento Therapeutics closes sale of ImmuneOncia shares to Yuhan
10/19/2023	DD	Sorrento Therapeutics’ disclosure statement conditionally approved
10/13/2023	DD	Sorrento Therapeutics seeks extension of exclusive plan periods
10/12/2023	DD	Sorrento Therapeutics files Chapter 11 plan and disclosure statement
10/11/2023	DD	Sorrento Therapeutics seeks approval to sell ImmuneOncia shares
10/5/2023	DD	Sorrento Therapeutics gets third extension of exclusive plan periods
9/21/2023	DD	Sorrento Therapeutics seeks exclusivity extension, closes Scilex stock sale
9/21/2023	DD	Sorrento Therapeutics seeks extension of exclusive plan periods
9/13/2023	DD	Sorrento Therapeutics gets OK to sell Scilex stock back to Scilex
9/11/2023	DD	Sorrento Therapeutics pivots away from sale of Scilex stock to Oramed
9/1/2023	DD	Sorrento gets more time to file plan under amended DIP order
8/28/2023	DD	Sorrento Therapeutics receives court approval to sell Scilex stock
8/25/2023	DD	Sorrento’s sale of Scilex stock to Oramed draws objection from Scilex
8/16/2023	DD	Sorrento Therapeutics posts $64.24 million net loss for June
8/14/2023	DD	Sorrento receives approval of Nant settlement, exclusivity extension
8/11/2023	DD	Sorrento seeks exclusivity extension, subsidiary DIP lender objects
8/7/2023	DD	Sorrento nixes Hundred Gain deal, lines up sale, financing via Oramed
7/28/2023	DD	Sorrento gets final approval of $20 million DIP loan via subsidiary
7/25/2023	DD	Sorrento lines up $200 million exit financing deal via Hundred Gain
7/21/2023	DD	Sorrento, equity committee launch offering to Scilex dividend short holders
7/14/2023	DD	Sorrento Therapeutics lender objects to proposed Scilex settlement
7/7/2023	DD	Sorrento Therapeutics receives asked-for exclusivity extension
7/6/2023	DD	Sorrento gets interim OK of $20 million DIP loan via subsidiary
7/3/2023	DD	Sorrento seeks approval of $20 million junior DIP loan via subsidiary
6/15/2023	DD	Sorrento Therapeutics records $13.27 million net loss for April
6/12/2023	DD	Sorrento Therapeutics seeks 59-day exclusivity extension
6/8/2023	DD	Sorrento settlement with Nant draws objection from DIP lender
6/7/2023	DD	Sorrento Therapeutics reaches settlement with Nant via mediation
5/19/2023	DD	Sorrento Therapeutics, Scintilla give operating results for March
5/2/2023	DD	Sorrento Therapeutics records $14.89 million net loss for February
4/14/2023	DD	Sorrento Therapeutics secures approval of three-prong bid procedures
4/11/2023	DD	Sorrento Therapeutics seeks approval of three-prong bid procedures
3/30/2023	DD	Sorrento Therapeutics to have official equity committee appointed
3/29/2023	DD	Sorrento Therapeutics gets final approval of $75 million DIP loan
3/28/2023	DD	Sorrento Therapeutics: Court kicks NantCell off creditors committee
3/24/2023	DD	Sorrento unsecured creditors object to equity committee appointment
3/17/2023	DD	Sorrento Therapeutics equity holders want official representation
3/17/2023	DD	Sorrento Therapeutics wins $125 million arbitration award against NantPharma
3/16/2023	DD	Sorrento Therapeutics: U.S. trustee says NantCell should stay on committee
3/13/2023	DD	Sorrento Therapeutics asks court to remove NantCell from committee
2/23/2023	DD	Sorrento Therapeutics asks bankruptcy court to appoint mediator
2/21/2023	DD	Sorrento Therapeutics gets interim OK of $75 million DIP financing
2/21/2023	DD	Sorrento Therapeutics seeks approval of $75 million DIP financing
2/17/2023	BKCVDDEMHY	Prospect News reports five new defaults for Feb. 9-Feb. 15
2/16/2023	DD	Sorrento Therapeutics gets approval of some first-day motions
2/13/2023	DD	Sorrento Therapeutics files bankruptcy following legal disputes

©2026 Prospect News. This page is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies, faxing, photocopying or any other form of reproduction.